India-based drugmaker Lupin has signed an agreement with Polish biopharmaceutical firm Celon Pharma to develop a fluticasone / salmeterol dry powder inhaler (DPI).

Under the deal, Lupin will take the responsibility for commercialisation of the product, which is a generic version of GlaxoSmithKline’s (GSK) Advair Diskus.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Lupin CEO Vinita Gupta said: "We are very pleased to partner with Celon given their experience in the development and manufacturing of fluticasone/salmeterol DPI in Europe.

"This coupled with Lupin’s expertise in inhalation product development and commercialisation in the US and other markets will accelerate the development of generic Advair Diskus for global markets."

"This coupled with Lupin’s expertise in inhalation product development and commercialisation in the US and other markets will accelerate the development of generic Advair Diskus for global markets."

The DPI product will be supplied by Celon to Lupin for its commercialisation in the US, Canada, and Mexico, as well as other key markets.

As of last fiscal year, Advair Diskus reported global sales of around $7bn, according to Lupin.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Celon Pharma CEO and managing director Maciej Wieczorek said: "Our scientific and technical teams look forward to collaborating with Lupin to bring this product to major markets outside of Poland.

"We are enthusiastic and believe that both the companies would work together to complete a time bound research and development programme to ensure successful registration in targeted markets, for Lupin to effectively commercialise the product."

Lupin provides drugs in the cardiovascular, diabetology, asthma, paediatric, CNS, GI, anti-infective and NSAID space, as well as holds significant position in the anti-TB and cephalosporin segment.